Business
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also ...
About this update from Lexaria Bioscience Corp.
[{"type":"list","items":[{"val":[{"type":"text","content":"More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound®","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide.","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":429,"olType":false},{"type":"text","content":"KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive pharmacokinetic ("PK") results from Human Study #3 or GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®.","length":466,"tagName":"p"},{"type":"text","content":"Zepbound® is currently only available as a once-weekly injection for weight loss. It is not sold by Eli Lilly in any oral format. Lexaria's Study was designed to discover whether the active drug within Zepbound® - tirzepatide - could be administered using Lexaria's patented DehydraTECH drug delivery technology via simple oral capsules in order to deliver a useful quantity of tirzepatide into the human bloodstream, as well as provide a viable alternative to disliked injections. The results were unexpectedly positive, showing that orally delivered DehydraTECH-tirzepatide reached roughly equal end of Study blood-concentration levels as the injected drug.","length":667,"tagName":"p"},{"type":"text","content":"During the 8-day Study, data was successfully collected from 10 people who were dosed with a single weekly injection of Zepbound®, and from 9 people who were dosed daily over the same one-week duration with DehydraTECH-tirzepatide capsules.","length":240,"tagName":"p"},{"type":"text","content":"In general, the peak levels of blood delivery of the injected Zepbound® were, for the most part, higher than that...